Evidence map›Paper›PMID 40916147›Full record

ArticleBiotechnology journal2025

Bacterial Glutamine Synthetases as a Novel Metabolic Selection Marker to Improve CHO Cell Culture Performance Through Selection Stringency Modulation.

Daniel Heinzelmann, Nicholas Michelarakis, Franziska Reuss, Benjamin Lindner, Anne R Karow-Zwick, Joschka Bauer, Benjamin Renner, Simon Fischer, Patrick Schulz, Moritz Schmidt

Abstract read
In one paragraph

Article in Biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daniel HeinzelmannBioprocess Development Biologicals, Cell Line Development, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.ORCID https://orcid.org/0000-0001-5431-1398
Nicholas MichelarakisPharmaceutical Development Biologicals, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.
Franziska ReussBioprocess Development Biologicals, Cell Line Development, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.
Benjamin LindnerBioprocess Development Biologicals, Cell Line Development, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.ORCID https://orcid.org/0000-0002-4609-3105
Anne R Karow-ZwickPharmaceutical Development Biologicals, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.
Joschka BauerPharmaceutical Development Biologicals, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.
Benjamin RennerBioprocess Development Biologicals, Cell Line Development, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.
Simon FischerBioprocess Development Biologicals, Cell Line Development, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.ORCID https://orcid.org/0000-0002-5188-7620
Patrick SchulzBioprocess Development Biologicals, Cell Line Development, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.
Moritz SchmidtBioprocess Development Biologicals, Cell Line Development, Boehringer Ingelheim GmbH & Co. KG, Biberach, Germany.ORCID https://orcid.org/0000-0002-1933-1999

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of metabolic selection markers has advanced stable cell line generation, increasing productivity while simultaneously eliminating the need for antibiotic reagents. This study explores the potential of bacterially derived glutamine synthetases (GS) as a novel generation of metabolic selection markers to further enhance CHO cell culture performance. GS-I proteins were extracted from the genomes of enterobacterial and actinomycetes species. Three of these enzymes demonstrated functionality when stably transfected into GS-deficient CHO cells, leading to a 3- to 4-fold increase in antibody titer compared to endogenous GS from Cricetulus griseus. This study indicates that the functionality of bacterial GS enzymes in mammalian cells is determined by solvent accessibility and the geometry of the catalytic binding pocket. Dysfunctional variants showed a less accessible bifunnel. Bacterial GS were evaluated for their bioprocess performance leading to superior stable pool and clone performance. Transcriptome analysis further revealed that regulatory cellular mechanisms were decoupled in a cross-species set-up, reinforcing the suitability of repurposing bacterial enzymes as selection markers in mammalian cell lines. By modulating the selection stringency, an increase in expression performance was achieved without impairing the bioprocess behavior or long-term cell line stability.

Indexed as

Bacterial ProteinsCell Culture TechniquesGlutamate-Ammonia LigaseAnimalsCHO CellsCricetulusBacterial ProteinsGlutamate-Ammonia Ligasecell culture performancecell line stabilityChinese hamster ovary cellsglutamine synthetasehomology modellingmetabolic selection markermolecular simulation

Identifiers

PMID40916147
PMCPMC12415323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.